VRCA Latest Press Releases

-- November 5, 2026 --

Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 Globe Newswire 8:00 AM

-- October 22, 2026 --

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility Globe Newswire 8:00 AM

-- September 30, 2026 --

Verrica Pharmaceuticals to Present New YCANTH Data Analysis at Two Upcoming Dermatology Conferences Globe Newswire 8:00 AM

-- September 10, 2026 --

Verrica Pharmaceuticals to Present YCANTH and VP-315 Data at Two Upcoming Dermatology Conferences Globe Newswire 8:05 AM

-- September 8, 2026 --

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 8:00 AM

-- August 27, 2026 --

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH for the Treatment of Common Warts, with Topline Data Expected Q1 2027 Globe Newswire 8:00 AM

-- August 6, 2026 --

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results Globe Newswire 4:05 PM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital Globe Newswire 4:01 PM

-- July 30, 2026 --

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 Globe Newswire 8:00 AM

-- July 21, 2026 --

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH for the Treatment of Molluscum Contagiosum in Israel Globe Newswire 8:00 AM

-- June 22, 2026 --

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts Globe Newswire 8:05 AM

Market Data Delayed 15 Minutes